Heart failure (HF) impacts more than 6 million Americans with an annual mortality rate
approaching 22%. Along with optimizing guideline‐directed management and therapy …

Objective This systematic review and meta-analysis was performed to compare the effect of
sodium-glucose cotransporter protein-2 inhibitors (SGLT-2i) and placebo on left ventricular …

Abstract The Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure (DAPA‐
HF) study demonstrated that dapagliflozin, a sodium‐glucose cotransporter‐2 inhibitor …

Sodium-glucose cotransporter 2 inhibitors (SGLT2is) are newly emerging insulin-
independent anti-hyperglycemic agents that work independently of β-cells. Quite a few large …

Abstract Background and Objective In recent trials, sodium-glucose cotransporter 2 (SGLT2)
inhibitors proved effective as treatment for heart failure. However, the relative efficacy of …

To investigate the effects of Dapagliflozin on myocardial remodeling, inflammatory factors,
and cardiac events in the treatment of heart failure with preserved ejection fraction (HFpEF) …

Background: Sodium-glucose cotransporter 2 (SGLT2) inhibitors have shown promise in
improving cardiovascular outcome in patients with heart failure (HF) and diabetes mellitus …

Following the results observed in the DAPA‐HF trial and subsequent FDA approval of
dapagliflozin in patients living with heart failure with reduced ejection fraction (HFrEF) …

Background Acute myocardial infarction (AMI) poses a significant threat to cardiovascular
diseases (CVDs), leading to a high risk of heart failure (HF) and cardiovascular death …

Background Cardiovascular disease threatens the health and quality of life of individuals,
particularly those with type II diabetes. Recently, some studies have reported the effect of …